US1710774076
© BusinessWire
22.12.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast (QUB), further strengthening...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen® Beauty, the first-ever beauty supplement in the US featuring Niagen (patented nicotinamide riboside or NR) — the most efficient, effective, and high quality...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eClinicalMedicine demonstrating that daily supplementation with Niagen®,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
06.11.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces $10 Million Share Repurchase Program
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximate...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
04.11.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
News Preview
Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025.
Third Quarter 2025 Financial Highlights Compared to Prior Year Period
Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%.
Gross margin increased 100 basis points to 64.5%.
Sales and marketing ex...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 20...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through Nutri...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclus...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15th Annual London Conference, which will be held at the Four Seasons Hotel London at Park Lane in Lond...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Participate in the BIO 2025 International Convention
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts.
Hosted by the Biotechnology Innovati...
Themefolio
Profiler
Peergroup
© BusinessWire
09.06.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and K...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
04.06.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer’s 25th Annual Consumer Growth and E-C...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
News Preview
Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025.
First Quarter 2025 Financial and Recent Operational Highlights
Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter.
Total Niagen® ingredient sales, including foo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
News Preview
Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics now offering pharmaceutical-grade Niagen® IV and injections featuring patente...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).
Dr. Cohen is an internationally recognized leading expert in healthy...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31,...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reaffirms that the manufacturing of its Niagen® ingredient (patented nicotinamide riboside or NR) and Tru Niagen® and pharmaceutical-grade Niagen® products remain resilien...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
CDXC
LISTED
NASDAQ
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of ma...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
CDXC
LISTED
NASDAQ
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
News Preview
Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) and the Company’s common stock will begin trading under...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
CDXC
LISTED
NASDAQ
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effective at stock market open on Wednesday, March 19, 2025.
As part of this tr...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
CDXC
LISTED
NASDAQ
ChromaDex to Present at the 37th Annual Roth Conference
News Preview
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference.
ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
CDXC
LISTED
NASDAQ
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
News Preview
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results.
Fourth Quarter 2024
Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter.
Posted strong gross margin of 62.5%, up 150 basis points from 61.0% in the prior year quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
CDXC
LISTED
NASDAQ
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 202...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
CDXC
LISTED
NASDAQ
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
News Preview
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
The company present...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
CDXC
LISTED
NASDAQ
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
News Preview
ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large.
This recognition underscores ChromaDex...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
CDXC
LISTED
NASDAQ
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
News Preview
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology’s inaugural supplement called Longevity.Technology® LONGEVITY. Designed to...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
CDXC
LISTED
NASDAQ
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. T...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
CDXC
LISTED
NASDAQ
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
News Preview
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024.
Third Quarter 2024 Financial and Recent Operational Highlights
Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter.
Total Niagen® ingredient sales, including food-grade a...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
CDXC
LISTED
NASDAQ
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
News Preview
ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
CDXC
LISTED
NASDAQ
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be r...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
CDXC
LISTED
NASDAQ
ChromaDex to Participate in the 17th Annual LD Micro Main Event
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. The event is expected to feature 150 companies, presenting in ha...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
CDXC
LISTED
NASDAQ
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex’s Global Director of External Research, as the winner of the inaugural Trailblazing Wo...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
CDXC
LISTED
NASDAQ
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
CDXC
LISTED
NASDAQ
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer.
Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public mar...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
CDXC
LISTED
NASDAQ
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen® (nicotinamide riboside chloride or NRC), branded Niagen+, in intravenous (IV) and injectable...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
CDXC
LISTED
NASDAQ
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a century, ChromaDex has been at the forefront of analytical chemistry and scientific innovation, dedicated to unlocking the full potential of NAD+ to promo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
CDXC
LISTED
NASDAQ
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, August 29, 2024, at 2:00 PM...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
CDXC
LISTED
NASDAQ
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
News Preview
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the broadening of its NAD+ precursor intellectual property portfolio with the newly granted U.S. Patent number 10,000,520 C1 covering the composition of matter for the disodium salt of NMNH (dihydr...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
